Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Accumulated Expenses (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed Accumulated Expenses for 7 consecutive years, with $46000.0 as the latest value for Q3 2025.

  • For Q3 2025, Accumulated Expenses fell 36.11% year-over-year to $46000.0; the TTM value through Sep 2025 reached $46000.0, down 36.11%, while the annual FY2024 figure was $33000.0, 95.86% down from the prior year.
  • Accumulated Expenses hit $46000.0 in Q3 2025 for Cyclerion Therapeutics, down from $266000.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $4.8 million in Q2 2022 and bottomed at $22000.0 in Q1 2024.
  • Average Accumulated Expenses over 5 years is $1.4 million, with a median of $451000.0 recorded in 2021.
  • Year-over-year, Accumulated Expenses crashed 98.63% in 2024 and then surged 2327.27% in 2025.
  • Cyclerion Therapeutics' Accumulated Expenses stood at $3.2 million in 2021, then plummeted by 92.65% to $238000.0 in 2022, then soared by 235.29% to $798000.0 in 2023, then tumbled by 95.86% to $33000.0 in 2024, then surged by 39.39% to $46000.0 in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $46000.0, $266000.0, and $534000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.